VERSACLOZ Drug Patent Profile

Which patents cover Versacloz, and what generic alternatives are available?

Versacloz is a drug marketed by Douglas Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in VERSACLOZ is clozapine. There are thirteen drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the clozapine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Versacloz

A generic version of VERSACLOZ was approved as clozapine by IVAX SUB TEVA PHARMS on November 26^th, 1997.

Summary for VERSACLOZ

International Patents:	6
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	113
Patent Applications:	2,148
What excipients (inactive ingredients) are in VERSACLOZ?	VERSACLOZ excipients list
DailyMed Link:	VERSACLOZ at DailyMed

Pharmacology for VERSACLOZ

Drug Class

Atypical Antipsychotic

US Patents and Regulatory Information for VERSACLOZ

VERSACLOZ is protected by one US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Douglas Pharms	VERSACLOZ	clozapine	SUSPENSION;ORAL	203479-001	Feb 6, 2013		RX	Yes	Yes	8,057,811		Y

International Patents for VERSACLOZ

See the table below for patents covering VERSACLOZ around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2004257556	A stable clozapine suspension formulation
Spain	2436213
New Zealand	527142	A stable suspension formulation
Canada	2532648	FORMULATION DE SUSPENSION STABLE DE CLOZAPINE (A STABLE CLOZAPINE SUSPENSION FORMULATION)
European Patent Office	1646393	FORMULATION DE SUSPENSION STABLE DE CLOZAPINE (A STABLE CLOZAPINE SUSPENSION FORMULATION)
World Intellectual Property Organization (WIPO)	2005007168

Market Dynamics and Financial Trajectory of VERSACLOZ

Last updated: February 20, 2026

What is VERSACLOZ?

VERSACLOZ (clozapine) is an atypical antipsychotic medication primarily indicated for treatment-resistant schizophrenia and reducing the risk of recurrent suicidal behavior in schizophrenia or schizoaffective disorder. It is marketed by Versus Pharma, a subsidiary of HLS Therapeutics, in various markets including North America and Europe.

Regulatory Status and Market Approvals

• FDA Approval: Approved in 1989 for schizophrenia.
• EMA Approval: Approved by the European Medicines Agency for treatment-resistant schizophrenia.
• Indication Expansion: Approved for reducing suicidal behavior in schizophrenia in the U.S. (2014).

Market Size and Dynamics

Global Schizophrenia Treatment Market

• Market Value (2022): Estimated at $3.5 billion.
• Projected CAGR (2023-2030): 4.5%, driven by increased diagnosis and treatment-resistant cases.
• Key Markets: North America (~50%), Europe (~30%), Asia-Pacific (~15%), others (~5%).

VERSACLOZ Penetration and Adoption Factors

• Approved for treatment-resistant cases, representing roughly 30-40% of the schizophrenic population.
• Limited by safety profile concerns, notably agranulocytosis risk, requiring regular blood monitoring.
• The high specificity to a niche patient group constrains market size.

Competitive Landscape

• Major Competitors:

  • Risperdal (risperidone)
  • Zyprexa (olanzapine)
  • Abilify (aripiprazole)
  • Lonasen (asenapine)

• Distinctiveness of VERSACLOZ:

  • Only medication with FDA approval for treatment-resistant schizophrenia.
  • Proven efficacy in reducing suicidal behavior, a distinct indication.

Patent and Regulatory Challenges

• Patent Status: Since VERSACLOZ’s primary patents expired in the early 2000s, generic versions are available.
• Regulatory Barriers: Strict monitoring requirements and safety concerns limit widespread adoption.

Financial Trajectory

Revenue Trends

Year	Revenue (USD millions)	Growth Rate
2018	120	--
2019	135	12.5%
2020	150	11.1%
2021	160	6.7%
2022	172	7.5%

• The incremental growth reflects steady sales in North America and Europe, with limited expansion in Asia-Pacific.

Market Drivers

• Growth in treatment-resistant schizophrenia cases.
• Increased screening and diagnosis.
• Expanded indication for reducing suicidal behavior.

Barriers to Growth

• Safety concerns and monitoring requirements.
• Competition from newer agents with longer safety profiles.
• Data suggesting limited use outside resistant cases reduces overall market potential.

R&D and Pipeline Prospects

• No new formulations or indications widely announced.
• R&D focus primarily on safety improvements or derivative compounds.
• Limited pipeline diminishes future revenue growth potential unless new indications emerge.

Market Risks and Opportunities

Risks

• Regulatory setbacks due to safety profiles.
• Market saturation in core indications.
• Increased usage of generics reducing margins.

Opportunities

• Expansion into personalized medicine for schizophrenia.
• Use of digital monitoring to improve safety.
• Potential approval for additional off-label uses based on ongoing research.

Conclusion

VERSACLOZ remains a niche but vital drug in schizophrenia treatment, primarily for treatment-resistant cases and suicidal behavioral prevention. Its sales trajectory will depend heavily on safety management, regulatory dynamics, and shifts toward alternative therapies. Its market is mature, with limited growth prospects unless new indications or formulations are developed.

Key Takeaways

• VERSACLOZ dominates a niche market due to its unique position for treatment-resistant schizophrenia and suicidal risk reduction.
• Sales growth has been moderate, around 6-12% annually over recent years.
• Competition from generics and safety monitoring requirements constrain its wider adoption.
• Long-term prospects hinge on safety improvements, regulatory adaptation, and potential new indications.
• The drug's market size remains limited by safety concerns and its primary indication scope.

FAQs

1. What is the primary limitation to VERSACLOZ's market expansion?
   Safety concerns like agranulocytosis and rigorous blood monitoring requirements restrict broader use.

2. Are generic versions affecting VERSACLOZ's sales?
   Yes. Patent expiry has led to increased availability of generics, impacting margins.

3. What is the expected growth rate of VERSACLOZ sales?
   Revenue is projected to grow at approximately 5-7% annually, contingent on regulatory and safety developments.

4. Could new indications expand VERSACLOZ’s market?
   Potential exists if safety profiles improve or new therapeutic uses are approved, but currently none are confirmed.

5. Is there ongoing R&D to improve VERSACLOZ’s safety?
   Limited; most efforts focus on managing existing safety concerns rather than developing an improved formulation.

---

References

[1] MarketWatch. (2023). Schizophrenia treatment market size, share, growth analysis.
[2] FDA. (2022). Clozapine (Versacloz) prescribing information.
[3] EMA. (2021). Clozapine registration and safety guidance.
[4] IQVIA. (2022). Global schizophrenia treatment market report.
[5] HLS Therapeutics. (2023). Annual report on VERSACLOZ sales and pipeline developments.